Fujifilm's Avigan proves effective in Japanese Phase-3 trial for vaccine

TOKYO (Reuters) - Fujifilm Holdings Corp said on Wednesday its Avigan drug reduced viral loads and symptoms of COVID-19 patients, paving the way for regulatory approval in Japan after months of delays. The Phase 3 clinical study of 156 patients showed that those treated with Avigan improved after 11.9 days, versus 14.

7 days for a placebo group. Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were statistically significant, the company said in a release. Former Japanese Prime Minister Shinzo Abe had touted Avigan's.

This article is no longer available in our repository.

There could be multiple reasons for this.